



A global healthcare group dedicated to improving quality of life

www.daewoong.co.kr

Daewoong Pharmaceutical Co., Ltd.

CEO

Jeon Seng Ho

Location

Specialty

Bongeunsa-ro 114-gil 12 Gangnam-gu Seoul 06170 Korea Since 1945, we have grown into Korea's leading company in line with corporate philosophy of 'developing quality medicine to safeguard the people's health and contribute to a healthier society.' With \$1.3B revenues, we have 8 manufacturing sites globally and branches in China, Japan, In-

donesia, Thailand, Vietnam, Philippines, India and USA. We are the no.1 Korean player in Chinese

GI market, and we acquired the no.2 Vietnamese company (Traphaco). We have the first Halal

Main Products

Brands

Product name	Description	5-
Ursa®	Liver diseases & dysfunction improvement	
Bearse®	Multilayer digestives	Matta-

Biologics

biologics		
Product name	Description	
Easyef [®] (EGF)	Diabetic foot ulcer, Acute wounds	
Novosis [®] (rh BMP-2)	Dental sinus lift graft	
Caretropin [®] (hGH)	Growth hormone deficiency	
Eposis [®] (EPO)	Anemia in chronic kidney disease	
Nabota [®] (Botulinum toxin)	Anti-wrinkles	


certified Indonesian bio facility and a POC center in India.



Formulation

Product name	Description
Luphere [®] Depot	Peptide delivery system for prostate cancer
lostar	New combination drug for Hyperlipidemia/hypertension

R&D Pipeline



intractable disease

2. stem cell therapy for rare diseases (cell & gene therapy)

1. new chemical entities for

- 3. new formulation technology
- Tel / Fax / E-mail
- T. 82-2-550-8533
- F. 82-2-550-8400
- E. stomeve@daewoong.co.kr